Bharat Biotech shot shows high immune response, further study needed for elderly
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Bharat Biotech shot shows high immune response, further study needed for elderly

Coronavirus chronicle

Reuters
09 March, 2021, 09:25 pm
Last modified: 09 March, 2021, 09:28 pm

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Bharat Biotech shot shows high immune response, further study needed for elderly

The vaccine, India’s first successful home-made shot against Covid-19, has attracted interest from more than 40 countries

Reuters
09 March, 2021, 09:25 pm
Last modified: 09 March, 2021, 09:28 pm
Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called Covaxin, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi
Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called Covaxin, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi

A Covid-19 vaccine developed by India's Bharat Biotech is safe and has shown high levels of antibody response in a mid-stage trial, but follow-on studies are needed to evaluate the shot for children and older people, a peer-reviewed study showed.

The vaccine, India's first successful home-made shot against Covid-19, has attracted interest from more than 40 countries. The company said last week it had shown 81% efficacy in preventing symptomatic Covid-19, based on interim analysis of late stage trials.

The double-dose vaccine showed significantly higher neutralizing antibody responses in Phase II than in Phase I due to the difference in dosing regimens that changed to a 4-week apart injection schedule from a 2-week course, researchers said in the study published in medical journal Lancet on Monday.

But it said the Phase II trial, which had 380 participants, enrolled a small number of participants aged 12–18 years and 55–65 years and follow-on studies are required to establish immunogenicity in children and in older people.

It also said that while the trial included participants from across nine Indian states, the study population lacked ethnic and gender diversity, "underscoring the importance of evaluating BBV152 (the vaccine) in other populations".

Female participants, for example, accounted for just one quarter of the study subjects.

Its Phase III study, Bharat Biotech said last week, has 25,800 participants aged 18-98 and include more than 2,400 people over the age of 60.

The peer-reviwed study is another positive for Bharat Biotech, which had drawn criticism in January after the Indian government approved the vaccine, called COVAXIN, for emergency use without any efficacy data.

Less than 9% of the more than 18.2 million Indians vaccinated so far against Covid-19 had taken COVAXIN as of Tuesday, government data showed.

Many politicians in India, including Prime Minister Narendra Modi, have chosen to be inoculated with the homegrown shot instead of a rival one developed by AstraZeneca Plc and Oxford University.

India, the world's biggest vaccine maker, aims to inoculate 300 million of its 1.35 billion people by August. It has reported 11.24 million Covid-19 infections, the highest number in the world after the United States, with 157,930 deaths.

Top News

COVAXIN

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Project delays: The Sinohydro style 
    Project delays: The Sinohydro style 
  • Photo: TBS
    37,000 BO account holders sell all shares in 11 days
  • Photo: Reuters
    Monkeypox: Govt puts ports on alert 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine
  • A man checks phone at Lujiazui financial district in Pudong, Shanghai, China March 14, 2019. Photo :Reuters
    Shanghai inches towards Covid lockdown exit, Beijing plays defence
  • North Korean leader Kim Jong Un delivers opening remarks during the 2nd Conference of Secretaries of Primary Committees of the Workers' Party of Korea (WPK), in this photo released on February 27, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS/File Photo
    N Korea reports over 200,000 fever cases for 5th day amid Covid wave

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Features

The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

18h | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

20h | Panorama
Illustration: TBS

‘High logistics cost weakens Bangladesh’s competitiveness’

22h | Panorama
Every morning is a new beginning for all

Seashore

23h | In Focus

More Videos from TBS

Wheat prices double in India

Wheat prices double in India

12h | Videos
Is Washington-Moscow agreement possible?

Is Washington-Moscow agreement possible?

12h | Videos
Pigeon exhibition for the first time in Gazipur

Pigeon exhibition for the first time in Gazipur

17h | Videos
Photo: TBS

US Congress to hold first public UFO panel

19h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab